Fig. 3: CS1003 showed no ADCC or CDC activity.
From: CS1003, a novel human and mouse cross-reactive PD-1 monoclonal antibody for cancer therapy
The ADCC (a) and CDC (b) activities of CS1003 and pembrolizumab were evaluated. Herceptin-induced SK-Br-3 cell lysis and rituximab-induced Ramos cell lysis were used as positive controls for ADCC and CDC, respectively. CPM, counts per minute.
